Zhejiang Cancer Hospital
Clinical trials sponsored by Zhejiang Cancer Hospital, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Cord blood cells aim to heal Radiation-Damaged intestines Results expected Oct 2026 (estimated)
- Cord blood cells aim to heal Radiation-Damaged lungs Results expected Oct 2026 (estimated)
- Real-world study examines breast cancer drug's effectiveness outside clinical trials Results expected Dec 2026 (estimated)
- Glow-in-the-Dark dye could help surgeons spot hidden cancer Results expected Dec 2026 (estimated)
- Can a simple test predict immunotherapy outcomes for pancreatic cancer? Results expected Dec 2026 (estimated)
-
Can a Platinum-Free regimen beat nasopharyngeal carcinoma?
Disease control Not yet recruitingThis phase II trial tests a new treatment approach for people with locally advanced nasopharyngeal carcinoma, a type of head and neck cancer. The regimen avoids platinum-based chemotherapy, using a combination of gemcitabine, camrelizumab, endostar, and low-dose radiotherapy befo…
Phase 2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a Triple-Action therapy tackle stomach Cancer's spread?
Disease control Not yet recruitingThis phase II trial is testing whether a combination of low-dose radiation, an immunotherapy drug (serplulimab), and chemotherapy can help people with stomach cancer that has spread to the lining of the abdomen (peritoneal metastasis). The study enrolls adults with HER2-negative …
Phase 2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug cocktail aims to outsmart untreatable bile duct cancer
Disease control Not yet recruitingThis clinical trial tests a new approach for people with a type of bile duct cancer that cannot be removed by surgery. It compares a combination of targeted therapy and a procedure that delivers chemotherapy directly to the liver against standard chemotherapy. The goal is to see …
Phase 3 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug senaparib tested in Real-World ovarian cancer study
Disease control Not yet recruitingThis study will observe 500 women with ovarian, fallopian tube, or primary peritoneal cancer who are taking the drug senaparib. Researchers will track side effects and how well the drug controls the cancer in real-world conditions, outside of a strict clinical trial. The goal is …
Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to tackle lung cancer brain metastases
Disease control Not yet recruitingThis study tests a combination of two drugs (Sac-TMT and a third-generation EGFR-TKI), with or without radiation, in 45 people with a specific type of advanced lung cancer (EGFR-mutated non-squamous NSCLC) that has spread to the brain and stopped responding to previous treatment.…
Phase 2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Cord blood cells aim to heal Radiation-Damaged intestines
Disease control Not yet recruitingThis early-phase trial tests whether umbilical cord blood cells can safely help people with chronic radiation enteritis, a painful gut condition caused by cancer radiation therapy. Ten adults who have had pelvic or abdominal radiation will receive three weekly infusions of these …
Early phase 1 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 26, 2026 18:44 UTC
-
Cord blood cells aim to heal Radiation-Damaged lungs
Disease control Not yet recruitingThis early-stage trial tests whether umbilical cord blood cells can safely treat lung damage caused by radiation therapy for cancer. Ten adults who have not improved with standard care will receive three weekly infusions of these cells. The main goal is to check safety and see if…
Early phase 1 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 26, 2026 18:20 UTC
-
AI tool aims to predict breast cancer drug success, sparing patients unnecessary side effects
Knowledge-focused Not yet recruitingThis study is developing an AI tool that analyzes tumor images, proteins, and patient data to predict whether a person with advanced HER2-positive or low-expression breast cancer will benefit from the targeted drug T-DXd. The goal is to avoid giving ineffective treatment, which c…
Sponsor: Zhejiang Cancer Hospital • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Blood test may spot returning cervical cancer before symptoms appear
Knowledge-focused Not yet recruitingThis study looks at whether pieces of tumor DNA and HPV DNA circulating in the blood can predict if cervical cancer will return after successful first-line treatment. Researchers will collect blood samples over time from 60 patients whose cancer has gone into complete remission. …
Sponsor: Zhejiang Cancer Hospital • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Why do some breast cancer patients quit hormone therapy? new study aims to find out
Knowledge-focused Not yet recruitingThis observational study will follow 300 premenopausal women with HR-positive early breast cancer who are already receiving ovarian function suppression (OFS) therapy as part of their routine care. Researchers want to see how many patients stop OFS within two years and why, and w…
Sponsor: Zhejiang Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:36 UTC